Drug Type Small molecule drug |
Synonyms Ladostigil hemitartrate, Ladostigil tartrate, Ladostigil tartrate (USAN) + [2] |
Target |
Mechanism MAO-A inhibitors(Monoamine oxidase A inhibitors), MAO-B inhibitors(Monoamine oxidase B inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H26N2O8 |
InChIKeyDZMNQRCPJKPTNC-KBYGAXRISA-N |
CAS Registry209394-46-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Phase 3 | AT | 01 Feb 2011 | |
Alzheimer Disease | Phase 3 | HR | 01 Feb 2011 | |
Alzheimer Disease | Phase 3 | RS | 01 Feb 2011 | |
Alzheimer Disease | Phase 3 | ES | 01 Feb 2011 | |
Amnesia | Phase 3 | DE | 01 Feb 2011 | |
Amnesia | Phase 3 | RS | 01 Feb 2011 | |
Amnesia | Phase 3 | AT | 01 Feb 2011 | |
Amnesia | Phase 3 | ES | 01 Feb 2011 | |
Amnesia | Phase 3 | HR | 01 Feb 2011 | |
Cognitive Dysfunction | Phase 2 | - | - |
Phase 2 | 200 | (Ladostigil Hemitartrate) | bazmtdsccm(btiqpkvxrn) = odrupaodud xorymvawqc (htiniwrjif, lafajqmktp - nmdvgyfbfm) View more | - | 30 Jul 2020 | ||
(Placebo) | bazmtdsccm(btiqpkvxrn) = sqfqvyvyai xorymvawqc (htiniwrjif, imggsaafao - ujhjyuoxkm) View more | ||||||
Phase 2 | 210 | (Ladostigil Hemitartrate) | yewwlqxdnw(wcjlrjrjuz) = uqzodayafd fomletmshz (ximemaqqja, gundiqtzuz - bgylvjpsob) View more | - | 15 Jun 2017 | ||
Placebo (Placebo Control) | yewwlqxdnw(wcjlrjrjuz) = crmskttous fomletmshz (ximemaqqja, fxybshcref - lfjgumnuhs) View more |